Atrophic vulvovaginitis in women aged 50 years and above, both current and non-users of hormone replacement therapy, attending a genitourinary medicine clinic.

Abstract

INTRODUCTION:

In women aged 50 years and over attending a genitourinary medicine (GUM) department the commonest presentation was with symptoms of vulval soreness, irritation or dryness. Atrophic vulvovaginitis (AVV) was the commonest diagnosis made. This study was undertaken to determine if the presence of AVV was related to the use, or not, of systemic hormone replacement therapy (HRT).

METHOD:

A prospective study was made of all women aged 50 years and over attending a GUM department over a 3-month period.

RESULTS:

Of the 124 women seen in this age group, 60 (40%) had AVV and 28 (23%) had vaginal candidiasis. No difference was found in current users or non-users of HRT.

CONCLUSION:

Accurate diagnosis is essential in women with vulval symptoms to ensure that appropriate therapy is given. In the present study symptomatic women aged 50 years and over were more likely to have AVV than candidiasis irrespective of their use of systemic HRT.

• Authors: Jean Tobin, Veerakathy Harindra
• Journal: The journal of family planning and reproductive health care (J Fam Plann Reprod Health Care) Vol. 28 Issue 3 Pg. 135-6 (Jul 2002) ISSN: 1471-1893 [Print] England
• PMID: 16259830 (Publication Type: Journal Article)

Chemical References

• Estradiol

Topics

• Aged
• Aged, 80 and over
• Atrophy (diagnosis, drug therapy)
• Estradiol (administration & dosage)
• Estrogen Replacement Therapy (adverse effects, statistics & numerical data)
• Female
• Humans
• Middle Aged
• Prospective Studies
• Risk Factors
• Vulvovaginitis (diagnosis, drug therapy)
• Women's Health Services